" 'Crunching data from published studies, the authors found that treating a lung-cancer patient with Erbitux, a drug that costs $80,000 for an 18-week regimen, prolongs survival by only 1.2 months,' the Wall Street Journal reports. The study, which estimates that the life of each American who dies or cancer could be extended by one year at the cost of $440 billion, was published in the Journal of the National Cancer Institute. The high cost and relatively low benefit points to 'one of the thorniest questions facing lawmakers working on the overhaul of the U.S. health-care system': reducing growing health care spending in the last months of patient's lives."  MORE >>